Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial Lauri M. Burroughs, Eneida.

Slides:

Advertisements

Similar presentations

Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative.

Advertisements

Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host.

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies Katarina Le.

Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning

Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

Jörg D. Seebach, Georg Stussi, Jakob R. Passweg, Fausto R

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K

Biology of Blood and Marrow Transplantation

Statistical Considerations in Studies of Late Effects in HCT

A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning.

Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial

Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative.

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant.

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts Kile Green, Kim Pearce, Rob.

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J

Treosulfan Based Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation for Treatment of Patients with Non-Malignant Diseases: Preliminary.

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen H.

Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic.

Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders Mi Kwon,

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Biology of Blood and Marrow Transplantation

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Thymoglobulin® Exposure Is Influencing CD4+ Immune Reconstitution As a Predictor for Improved Overall Survival in Pediatric Haematopoietic Cell Transplantation:

Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter.

Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders Lauri M. Burroughs, Akiko.

Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and Fludarabine Conditioning Junya Kanda, David.

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a.

High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma Adrian J.C. Bloor, Kirsty.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial Lauri M. Burroughs, Eneida R. Nemecek, Troy R. Torgerson, Barry E. Storer, Julie-An Talano, Jennifer Domm, Roger H. Giller, Akiko Shimamura, Colleen Delaney, Suzanne Skoda-Smith, Monica S. Thakar, K. Scott Baker, David J. Rawlings, Janet A. Englund, Mary E.D. Flowers, H. Joachim Deeg, Rainer Storb, Ann E. Woolfrey Biology of Blood and Marrow Transplantation Volume 20, Issue 12, Pages 1996-2003 (December 2014) DOI: 10.1016/j.bbmt.2014.08.020 Copyright © 2014 Terms and Conditions

Figure 1 CD3+ and CD33+ donor chimerism in 31 patients conditioned with treosulfan and fludarabine. Shown are the percent donor chimerism of sorted peripheral blood CD3+ (A) and CD33+ (B) subsets according to day after transplant. The open circles represent percent donor chimerism measured for patients who were given thymoglobulin (n = 22), and the closed circles represent percent donor chimerism measured for patients who were not given thymoglobulin (n = 9) in the regimen. Spline smoothed regression lines reflect the trend in mean chimerism over time, for patients given thymoglobulin (dashed line) and for patients not given thymoglobulin (solid line). Overlapping points at day 28, day 84, day 180, and 1 year and at 100% chimerism, are jittered slightly to improve visibility. Biology of Blood and Marrow Transplantation 2014 20, 1996-2003DOI: (10.1016/j.bbmt.2014.08.020) Copyright © 2014 Terms and Conditions

Figure 2 Acute and chronic GVHD. Shown is the cumulative incidence of acute GVHD grades II to IV (A) and acute GVHD grades III to IV (B) according to whether patients were given thymoglobulin (dashed line, n = 22) or not given thymoglobulin (solid line, n = 9) in the regimen. (C) Cumulative incidence of chronic GVHD. (D) Cumulative incidence of discontinuation of systemic immune suppression (Off ISS) after HCT. Biology of Blood and Marrow Transplantation 2014 20, 1996-2003DOI: (10.1016/j.bbmt.2014.08.020) Copyright © 2014 Terms and Conditions

Figure 3 Overall survival, disease-free survival, and TRM (n = 31). Shown are the Kaplan-Meir estimates of overall survival (solid line) and disease-free survival (dashed line) and the cumulative incidence of TRM (dotted line). Biology of Blood and Marrow Transplantation 2014 20, 1996-2003DOI: (10.1016/j.bbmt.2014.08.020) Copyright © 2014 Terms and Conditions